Carbohydrate and the cytokine response to 2.5 h of running

1997 ◽  
Vol 82 (5) ◽  
pp. 1662-1667 ◽  
Author(s):  
S. L. Nehlsen-Cannarella ◽  
O. R. Fagoaga ◽  
D. C. Nieman ◽  
D. A. Henson ◽  
D. E. Butterworth ◽  
...  
Keyword(s):  
Significant Interaction ◽  
Plasma Cortisol ◽  
Interleukin 1 ◽  
Cytokine Response ◽  
Controlled Study ◽  
Double Blind ◽  
Marathon Runners ◽  
Carbohydrate Ingestion ◽  
Cytokine Responses ◽  
Cytokine Levels

Nehlsen-Cannarella, S. L., O. R. Fagoaga, D. C. Nieman, D. A. Henson, D. E. Butterworth, R. L. Schmitt, E. M. Bailey, B. J. Warren, A. Utter, and J. M. Davis. Carbohydrate and the cytokine response to 2.5 h of running. J. Appl. Physiol. 82(5): 1662–1667, 1997.—This randomized, double-blind, placebo-controlled study was designed to determine the influence of 6% carbohydrate (C) vs. placebo (P) beverage ingestion on cytokine responses (5 total samples over 9 h) to 2.5 h of high-intensity running (76.7 ± 0.4% maximal O2uptake) by 30 experienced marathon runners. For interleukin-6 (IL-6), a difference in the pattern of change between groups was found, highlighted by a greater increase in P vs. C immediately postrun (753 vs. 421%) and 1.5 h postrun (193 vs. 86%) [ F(4,112) = 3.77, P = 0.006]. For interleukin-1-receptor antagonist (IL-1ra), a difference in the pattern of change between groups was found, highlighted by a greater increase in P vs. C 1.5 h postrun (231 vs. 72%) [ F(2,50) = 6.38, P = 0.003]. No significant interaction effects were seen for bioactive IL-6 or IL-1β. The immediate postrun plasma glucose concentrations correlated negatively with those of plasma cortisol ( r = −0.67, P < 0.001); postrun plasma cortisol ( r = 0.70, P < 0.001) and IL-6 levels ( r = 0.54, P = 0.003) correlated positively with levels of IL-1ra. Taken together, the data indicate that carbohydrate ingestion attenuates cytokine levels in the inflammatory cascade in response to heavy exertion.

scholarly journals Plasma-Soluble CD30 in Childhood Tuberculosis: Effects of Disease Severity, Nutritional Status, and Vitamin A Therapy

1999 ◽  
Vol 6 (2) ◽  
pp. 204-208 ◽  
Author(s):  
W. A. Hanekom ◽  
G. D. Hussey ◽  
E. J. Hughes ◽  
S. Potgieter ◽  
R. Yogev ◽  
...  
Keyword(s):  
Vitamin A ◽  
Nutritional Status ◽  
Disease Severity ◽  
Severe Disease ◽  
Clinical Signs ◽  
Controlled Study ◽  
Double Blind ◽  
Cytokine Responses ◽  
Soluble Cd30

ABSTRACT Plasma-soluble CD30 (sCD30) is the result of proteolytic splicing from the membrane-bound form of CD30, a putative marker of type 2 cytokine-producing cells. We measured sCD30 levels in children with tuberculosis, a disease characterized by prominent type 1 lymphocyte cytokine responses. We postulated that disease severity and nutritional status would alter cytokine responses and therefore sCD30 levels. Samples from South African children enrolled prospectively at the time of diagnosis of tuberculosis were analyzed. (Patients were originally enrolled in a randomized, double-blind placebo-controlled study of the effects of oral vitamin A supplementation on prognosis of tuberculosis.) Plasma samples collected at the time of diagnosis and 6 and 12 weeks later (during antituberculosis therapy) were analyzed. sCD30 levels were measured by enzyme immunoassay. The 91 children included in the study demonstrated high levels of sCD30 at diagnosis (median, 98 U/liter; range, 11 to 1,569 U/liter). Although there was a trend toward higher sCD30 levels in more severe disease (e.g., culture-positive disease or miliary disease), this was not statistically significant. Significantly higher sCD30 levels were demonstrated in the presence of nutritional compromise: the sCD30 level was higher in patients with a weight below the third percentile for age, in those with clinical signs of kwashiorkor, and in those with a low hemoglobin content. There was minimal change in the sCD30 level after 12 weeks of therapy, even though patients improved clinically. However, changes in sCD30 after 12 weeks differed significantly when 46 patients (51%) who received vitamin A were compared with those who had received a placebo. Vitamin A-supplemented children demonstrated a mean (± standard error of the mean) decrease in sCD30 by a factor of 0.99 ± 0.02 over 12 weeks, whereas a factor increase of 1.05 ± 0.02 was demonstrated in the placebo group (P = 0.02). We conclude that children with tuberculosis had high sCD30 levels, which may reflect the presence of a type 2 cytokine response. Nutritional compromise was associated with higher sCD30 levels. Vitamin A therapy resulted in modulation of sCD30 levels over time.

scholarly journals Idiopathic recurrent pericarditis – a new orphan autoinflammatory disease? A retrospective analysis of cases of idiopathic recurrent pericarditis and a design of а double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of RPH-104 treatment in patients with idiopathic recurrent pericarditis

Kardiologiia ◽  
2021 ◽  
Vol 61 (1) ◽  
pp. 72-77
Author(s):  
V.  Yu. Myachikova ◽  
A. L. Maslyanskiy ◽  
O. M. Moiseeva
Keyword(s):  
Retrospective Analysis ◽  
Autoinflammatory Disease ◽  
Current Knowledge ◽  
Interleukin 1 ◽  
Controlled Study ◽  
Recurrent Pericarditis ◽  
Double Blind ◽  
Postpericardiotomy Syndrome ◽  
Randomized Clinical Study ◽  
Pericardial Diseases

Aim To analyze cases of idiopathic recurrent pericarditis (IRP) in the structure of pericardial diseases of various origins from patient visits to the Multidisciplinary Federal Center.Material and methods A retrospective analysis of case records was performed for patients admitted to the V.A. Almazov National Medical Research Center from January 1, 2015 through January 1, 2020 for pericardial effusion of different etiologies.Results For the study period, 4 981 new cases of pericardial damage of different etiologies were found. Among these cases, postpericardiotomy syndrome accounted for 4 360 cases and pericarditis for 621 cases. IRP was detected in 34 cases, which amounted to 5.4 %. Based on the study data, the estimated IRP prevalence in the Russian Federation can be 1.1 cases per 100 thousand population.Conclusion IRP should be regarded as a new autoinflammatory disease, the prevalence of which borders on that of adult Still disease and should be addressed within the concept of orphan diseases. Current knowledge of the pathogenesis and data from recent studies demonstrated a great importance of interleukin-1 blockade as a leading mechanism for achieving remission. This has justified conduction of a randomized clinical study at the Center.

scholarly journals Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers

Blood ◽  
1995 ◽  
Vol 85 (9) ◽  
pp. 2482-2489 ◽  
Author(s):  
T Hartung ◽  
WD Docke ◽  
F Gantner ◽  
G Krieger ◽  
A Sauer ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Interleukin 1 ◽  
Randomized Study ◽  
Muramyl Dipeptide ◽  
Cytokine Response ◽  
Complement Factor ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Double Blind ◽  
Stimulating Factor

We explored the ex vivo alteration in the cytokine release of stimulated blood taken from healthy volunteers treated subcutaneously with 480 micrograms granulocyte colony-stimulating factor (G-CSF). In a double-blind, controlled, randomized study with 21 volunteers who received G-CSF once or twice 24 hours apart, we measured lipopolysaccharide (LPS)-inducible release of various cytokines and soluble receptors at different times after treatment. At day 1 after a single dose of G-CSF, mediator release was also initiated with muramyl dipeptide, Staphylococcus aureus enterotoxin A, lipoteichoic acid, streptolysin O, complement factor C5a, phytohemagglutinin, or phorbol myristate acetate. In blood from G-CSF-treated subjects, our major findings were (1) a maximal 12-fold increase in interleukin-1 receptor antagonist (IL-1ra) release and an increase of both the p55 and p75 soluble tumor necrosis factor (TNF) receptors; (2) a reduction in TNF release when using all the various stimuli described except LPS; (3) an increase in G-CSF and, to lesser extent, in IL-6, IL-8, and IL-10 release; and (4) an attenuation of interferon-gamma (IFN-gamma) and granulocyte-macrophage (GM)-CSF release. Our findings demonstrate that the major effect of G-CSF treatment is a change in the responsiveness of blood towards a variety of stimuli, which we interpret as a shift toward an antiinflammatory cytokine response.

scholarly journals A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor Receptor Antagonist) in Patients with Severe Sepsis

2000 ◽  
Vol 44 (3) ◽  
pp. 693-696 ◽  
Author(s):  
Yupin Suputtamongkol ◽  
Sunanta Intaranongpai ◽  
Michael D. Smith ◽  
Brian Angus ◽  
Wipada Chaowagul ◽  
...  
Keyword(s):  
Severe Sepsis ◽  
Receptor Antagonist ◽  
Controlled Trial ◽  
Platelet Activating Factor ◽  
Blood Cultures ◽  
Controlled Study ◽  
Double Blind ◽  
Cytokine Levels ◽  
Paf Receptor ◽  
Paf Receptor Antagonist

ABSTRACT Platelet-activating factor (PAF) is a potent endogenous proinflammatory mediator implicated in the pathogenesis of septic shock. A double-blind randomized placebo-controlled trial of an intravenous PAF receptor antagonist (lexipafant) was conducted with 131 adult Thai patients with suspected severe sepsis (66 of whom had positive blood cultures). Detailed serial clinical, biochemical, and cytokine measurements were performed. Lexipafant treatment was well tolerated. The 28-day mortality in the lexipafant group (61.4%) was similar to that in the placebo group (62.6%). There was also no evidence that lexipafant affected clinical or biochemical measures of disease severity or the profile of sequentially measured plasma cytokine levels. PAF may not have an important role in the pathogenesis of severe sepsis.

scholarly journals Effects of Probiotic Supplementation on Selected Parameters of Blood Prooxidant‐Antioxidant Balance in Elite Athletes: A Double‐Blind Randomized Placebo‐Controlled Study

2018 ◽  
Vol 64 (1) ◽  
pp. 111-122 ◽  
Author(s):  
Danica Michalickova ◽  
Jelena Kotur-Stevuljevic ◽  
Milica Miljkovic ◽  
Nenad Dikic ◽  
Marija Kostic-Vucicevic ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Interaction Effect ◽  
Significant Interaction ◽  
Elite Athletes ◽  
Controlled Study ◽  
Pon1 Activity ◽  
Double Blind ◽  
Significant Interaction Effect ◽  
Probiotic Group ◽  
Ldl Particles

AbstractA randomized, double-blind, placebo-controlled study was conducted, in order to evaluate if Lactobacillus helveticus Lafti® L10 (Lallemand Health Solutions, Montreal, Canada) supplementation during three months could influence oxidative markers in the population of elite athletes: triathletes, cyclists and endurance athletes. Twenty-two elite athletes were randomized to either placebo (n = 12) or probiotic (n = 10) groups. The probiotic group received 2x1010 colony forming units of Lafti® L10. Before and after the supplementation serum samples were collected. Markers of oxidative stress and anti-oxidative defense: superoxide dismutase (SOD), paraoxonase (PON), advanced oxidation protein products (AOPP), malondialdehyde (MDA), total antioxidant status, total oxidant status, pro-oxidant-antioxidant balance, oxidative stress index, bilirubin, uric acid and albumin were determined in serum. Parameters of lipid status, as well as susceptibility to copper-induced oxidation of LDL particles in vitro were also determined. There was a significant interaction effect for MDA (p = 0.039), with a decrease in MDA in the probiotic group only (p = 0.049). There was a significant interaction effect for AOPP (p = 0.037), with a significant decrease in the probiotic group (p = 0.045). Interaction effect for SOD was approaching to formal significance (p = 0.108) and the post-hoc test showed a significant decrease in the probiotic group (p = 0.041) only. A significant correlation between AOPP and SOD (p = 0.012, r = -0.40) was found in the probiotic group at the end of the study. PON1 activity was decreased in both the probiotic (p = 0.032) and placebo group (p = 0.035). No significant changes in the remainder of the evaluated parameters were noted. In conclusion, probiotic strain Lafti® L10 exerts certain antioxidant potential, but further research is needed.

scholarly journals Ingestion of Exopolymers fromAureobasidium pullulansReduces the Duration of Cold and Flu Symptoms: A Randomized, Placebo-Controlled Intervention Study

2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Jong-Min Lim ◽  
Eunju Do ◽  
Dong-Chan Park ◽  
Go-Woon Jung ◽  
Hyung-Rae Cho ◽  
...  
Keyword(s):  
Functional Food ◽  
Intervention Study ◽  
Influenza Season ◽  
Controlled Study ◽  
Serum Cytokine ◽  
Double Blind ◽  
Food Material ◽  
Significance Level ◽  
Cytokine Levels ◽  
Primary Variable

Aim. The objective of the study was to assess the efficacy of exopolymers fromAureobasidium pullulans(EAP) on the incidence of colds and flu in healthy adults.Methods. We conducted a randomized, double-blind, placebo-controlled study at the onset of the influenza season. A total of 76 subjects (30–70 years of age) were recruited from the general population. The subjects were instructed to take one capsule per day of either EAP or a placebo for a period of 8 weeks. The duration of cold and flu symptoms, a primary variable in assessing effectiveness, and serum cytokine levels as well as WBC counts as secondary variables were also evaluated.Results. EAP was associated with a statistically significant decrease in the duration of cold and flu symptoms, a primary variable in assessing effectiveness. Although cold and flu symptom levels were not significantly different at a significance level of 5%, the cold and flu symptom levels of the EAP group were less severe compared to the placebo group. No statistically significant changes of serum cytokine levels as well as WBC counts were observed.Conclusion. The results showed that EAP is a useful pharmaceutical and functional food material for preventing and treating colds and flu.

Sign in / Sign up

Export Citation Format

Share Document